Patent application number | Description | Published |
20090027584 | LIQUID CRYSTAL DISPLAY WITH A BACKLIGHT ASSEMBLY HAVING AN IMPROVED STRUCTURE - A liquid crystal display with improved backlight structure is presented. The liquid crystal display includes a liquid crystal (LC) panel for displaying image, a backlight assembly for providing light to the LC panel and a top frame combined with the bottom frame to complete LCD assembling. The backlight assembly includes a bottom frame, light source, and optical member. The bottom frame includes a light source receiving part, a side wall and a optical member receiving part which extends inwardly to the inner side of the backlight assembly. Thus, the overall size of the LCD can be reduced. | 01-29-2009 |
20100039579 | LIQUID CRYSTAL DISPLAY WITH LIGHT EMITTING DIODE BACKLIGHT ASSEMBLY AND LIQUID CRYSTAL DISPLAY THEREOF - A light emitting diode (“LED”) backlight assembly. The LED backlight assembly has a bottom container which has a bottom plate and a side edge surrounding the bottom plate, a plurality of light emitting diode printed circuit boards (“LED-PCBs”) on the bottom plate, and a connector which is closely located to edge located LEDs. The connector of the LED-PCB is closely located to an LED driving board, which is disposed at a lateral space of a lateral part of the bottom container to limit a vertical thickness of the backlight light assembly. | 02-18-2010 |
20100085734 | BACKLIGHT ASSEMBLY AND FLAT PANEL DISPLAY APPARATUS HAVING THE SAME - In a backlight assembly and a flat panel display apparatus, the backlight assembly has a diffusing plate, a supporting member and reflecting plate. The supporting member has a base body portion, a supporting portion supporting the diffusing plate and a lamp holder receiving lamps to uniformly maintain spaced intervals between the lamps. The base body portion is disposed under the reflecting plate. The supporting portion and the lamp holder are inserted through engaging openings formed at the reflecting plate such that the supporting portion and the lamp holder are upwardly protruded with respect to the reflecting plate. Accordingly, the backlight assembly may reduce an area of the reflecting plate covered by the supporting member, thereby providing the light having uniform brightness distribution. | 04-08-2010 |
20100157194 | LAMP SOCKET, BACKLIGHT ASSEMBLY INCLUDING THE LAMP SOCKET, AND LIQUID CRYSTAL DISPLAY INCLUDING THE BACKLIGHT ASSEMBLY - A lamp socket includes a lamp connection unit which is electrically connected to a lamp, a power connection unit which is disposed below and adjacent to the lamp connection unit along a longitudinal axis and is electrically connected to an electric source which supplies power to the lamp, and a fastening member which is disposed on the power connection unit, wherein the power connection unit comprises at least one sub-component which has a surface area perpendicular to the longitudinal axis which is larger than the largest surface area of the lamp connection unit perpendicular to the longitudinal axis and wherein the sub-component of the power connection unit with the largest surface area perpendicular to the longitudinal axis is located proximate to the lamp connection unit. | 06-24-2010 |
20100245710 | CHASSIS AND DISPLAY DEVICE HAVING SAME - A chassis set includes a first chassis and a second chassis. The first chassis includes a first connecting portion having at least one guide protrusion. The second chassis includes a second connecting portion having at least one guide hole that receives the guide protrusion of the first chassis to combine the first and second chassis. Therefore, a manufacturing cost is reduced and productivity is enhanced. Additionally, the chassis can be made easily. | 09-30-2010 |
20110058118 | BACKLIGHT ASSEMBLY WITH A REFLECTIVE MEMBER COVERING INTERFACE BETWEEN SUBSTRATE UNITS - A backlight assembly capable of reducing light loss is presented. The backlight assembly includes a plurality of substrate units and a plurality of reflective members on the substrate units arranged to form an adjacent area where two reflective members are closest to each other. The adjacent area is on one of the substrate units. A display device incorporating the backlight assembly is also presented. | 03-10-2011 |
20110116009 | LAMP SOCKET, BACKLIGHT ASSEMBLY INCLUDING THE LAMP SOCKET, AND LIQUID CRYSTAL DISPLAY INCLUDING THE BACKLIGHT ASSEMBLY - A lamp socket includes a lamp connection unit which is electrically connected to a lamp, a power connection unit which is disposed below and adjacent to the lamp connection unit along a longitudinal axis and is electrically connected to an electric source which supplies power to the lamp, and a fastening member which is disposed on the power connection unit, wherein the power connection unit comprises at least one sub-component which has a surface area perpendicular to the longitudinal axis which is larger than the largest surface area of the lamp connection unit perpendicular to the longitudinal axis and wherein the sub-component of the power connection unit with the largest surface area perpendicular to the longitudinal axis is located proximate to the lamp connection unit. | 05-19-2011 |
20120301548 | ORAL COMPLEX COMPOSITION COMPRISING PSEUDOEPHEDRINE AND LEVOCETIRIZINE - An oral complex composition which comprises (i) a core comprising a swellable hydrogel-forming agent and pseudoephedrine, or a pharmaceutically acceptable salt thereof; (ii) a first coating layer encasing the core which comprises a water-soluble substance; and (iii) a second coating layer deposited on the first coating layer which comprises levocetirizine or a pharmaceutically acceptable salt thereof together with polyvinylalcohol, povidone, polyvinylalcohol-polyethyleneglycol graft copolymer or a mixture thereof, has an improved levocetirizine releasing rate and does not show a delayed release behavior even after a long storage period. Accordingly, the inventive oral complex composition is useful for treating perennial or seasonal allergic diseases including nasal obstruction, sneezing, and rhinorrhea. | 11-29-2012 |
20120301549 | COMPLEX FORMULATION COMPRISING ASPIRIN COATED WITH BARRIER CONTAINING HYDROPHOBIC ADDITIVE, AND HMG-COA REDUCTASE INHIBITOR - Provided is a complex formulation for the prevention or treatment of cardiovascular diseases, comprising: a) aspirin coated with a barrier containing a hydrophobic additive; and b) an HMG-CoA reductase inhibitor, which has improved storage stability by preventing the deterioration in the stability of HMG-CoA reductase which is caused by salicylic acid, thereby being used in the treatment of hypertension and hypercholesterolemia. | 11-29-2012 |
20120321709 | COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF - Disclosed are a complex formulation for oral administration comprising probiotic formulation and 5-HT4 receptor agonist, and a method for the preparation thereof. | 12-20-2012 |
20130022684 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING FENOFIBRIC ACID AND AN ALKALIFYING AGENT - An oral pharmaceutical composition of the present invention comprising fenofibric acid or a pharmaceutically acceptable salt thereof, and 0.22 to 1 part by weight of an alkalifying agent based on 1 part by weight of fenofibric acid has improved bioavailability and a minimized absorption deviation in the gastrointestinal tract, which is useful in treating hyperlipidemia and hypertriglyceridemia. | 01-24-2013 |
20130028974 | PHARMACEUTICAL FORMULATION IN THE FORM OF BILAYERED TABLETS COMPRISING HMG-COA REDUCTASE INHIBITOR AND IRBESARTAN - Provided is a pharmaceutical formulation in the form of a bilayered tablet consisting of a first layer containing irbesartan or a pharmaceutically acceptable salt thereof and a second layer containing an HMG-CoA reductase inhibitor and a basic additive, which can improve the dissolution rate and stability of irbesartan and an HMG-CoA reductase inhibitor to enhance the bioavailability of the drug compared to conventional complex formulations and to minimize the generation of the related compounds, thereby being effectively used as a stable and superior therapeutic agent for hypertension and hypercholesterolemia. | 01-31-2013 |
20130071452 | PHARMACEUTICAL COMPOSITION COMPRISING AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention relates to a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof, and an acidic additive. This composition, owing to improved stability even after a long-term storage, is suitable for inhibiting the growth of cancer cells. | 03-21-2013 |
20130243872 | PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING HMG-COA REDUCTASE INHIBITOR AND ASPIRIN - Provided is a pharmaceutical composite formulation for preventing or treating cardiovascular diseases, which comprises (1) a first particle comprising an HMG-CoA reductase inhibitor and a basic additive; and (2) a second particle comprising a core containing aspirin and an enteric coating layer coated on said core, wherein the difference in the average diameters of said first and second particles is 100 μm to 800 μm; a method for preparing same; and a method of validating the quality of same. The pharmaceutical composite formulation according to the present invention can improve the stability of an active ingredient and prevent adverse impacts between the active ingredients to thereby enable an accurate quality validation of the pharmaceutical composite formulation. | 09-19-2013 |
20130256793 | SEMICONDUCTOR DEVICES HAVING BIT LINE INSULATING CAPPING PATTERNS AND MULTIPLE CONDUCTIVE PATTERNS THEREON - A semiconductor device capable of reducing a thickness, an electronic product employing the same, and a method of fabricating the same are provided. The method of fabricating a semiconductor device includes preparing a semiconductor substrate having first and second active regions. A first transistor in the first active region includes a first gate pattern and first impurity regions. A second transistor the second active region includes a second gate pattern and second impurity regions. A first conductive pattern is on the first transistor, wherein at least a part of the first conductive pattern is disposed at a same distance from an upper surface of the semiconductor substrate as at least a part of the second gate pattern. The first conductive pattern may be formed on the first transistor while the second transistor is formed. | 10-03-2013 |
20130301234 | Chassis And Display Device Having The Same - A chassis set includes a first chassis and a second chassis. The first chassis includes a first connecting portion having at least one guide protrusion. The second chassis includes a second connecting portion having at least one guide hole that receives the guide protrusion of the first chassis to combine the first and second chassis. Therefore, a manufacturing cost is reduced and productivity is enhanced. Additionally, the chassis can be made easily. | 11-14-2013 |
20140010872 | ORAL COMPLEX COMPOSITION COMPRISING OMEGA-3 FATTY ACID ESTER AND HMG-COA REDUCTASE INHIBITOR - An oral complex composition comprising omega-3 fatty acid esters and HMG-CoA reductase inhibitor, can effectively raise serum HDL level while reducing serum LDL and TG levels and can be used to treat hyperlipidemia owing to its good drug dissolution rate and storage stability with showing no delayed release behavior even after 6 months of accelerated storage. | 01-09-2014 |
20140028952 | LIQUID CRYSTAL DISPLAY WITH LIGHT EMITTING DIODE BACKLIGHT ASSEMBLY AND LIQUID CRYSTAL DISPLAY THEREOF - A light emitting diode (“LED”) backlight assembly. The LED backlight assembly has a bottom container which has a bottom plate and a side edge surrounding the bottom plate, a plurality of light emitting diode printed circuit boards (“LED-PCBs”) on the bottom plate, and a connector which is closely located to edge located LEDs. The connector of the LED-PCB is closely located to an LED driving board, which is disposed at a lateral space of a lateral part of the bottom container to limit a vertical thickness of the backlight light assembly. | 01-30-2014 |
20140036479 | BACKLIGHT ASSEMBLY WITH A REFLECTIVE MEMBER COVERING INTERFACE BETWEEN SUBSTRATE UNITS - A backlight assembly capable of reducing light loss is presented. The backlight assembly includes a plurality of substrate units and a plurality of reflective members on the substrate units arranged to form an adjacent area where two reflective members are closest to each other. The adjacent area is on one of the substrate units. A display device incorporating the backlight assembly is also presented. | 02-06-2014 |
20140112962 | PHARMACEUTICAL COMPOSITION COMPRISING AMIDE DERIVATIVE INHIBITING THE GROWTH OF CANCER CELLS AND NON-METALLIC SALT LUBRICANT - Disclosed is a pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof and a non-metallic salt lubricant, which can be used as an effective cancer cell-growth inhibitor owing to its enhanced storage stability with no quality changes over time. | 04-24-2014 |
20140314844 | ORAL COMPLEX FORMULATION COMPRISING OMEGA-3 FATTY ACID AND HMG-COA REDUCTASE INHIBITOR WITH IMPROVED STABILITY - The present invention relates to an oral complex formulation comprising omega-3 fatty acid or its derivatives encapsulated in a hard or soft capsule containing sorbitol and sorbitan, as well as an HMG-CoA reductase inhibitor. The formulation of the present invention comprising omega-3 fatty acid encapsulated with sorbitol and sorbitan provides better prevention related materials from being formed, leading to improved long-term storage stability. The oral complex formulation of the present invention also can raise the serum HDL-cholesterol level, while reducing both LDL-cholesterol and TG levels. The oral complex formulation of the present invention is useful for treatment of hyperlipidemia. | 10-23-2014 |
20140356422 | STABLE PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION COMPRISING LEVOCETIRIZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MONTELUKAST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention relates to a pharmaceutical formulation for oral administration for preventing or treating allergic rhinitis or asthma, which comprises: (a) a first particle part comprising levocetirizine or a pharmaceutically acceptable salt thereof and an organic acid; and (b) a second particle part comprising montelukast or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation according to the present invention comprises an organic acid as a stabilizing agent, which can effectively inhibit the production of levocetirizine and montelukast related substances, and thus, show good stability. | 12-04-2014 |